InsidersTradesSigma
Follow the BETA BIONICS INC share price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €879.1m. The latest transaction was reported on 4 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: CHRISTINA JONES. Every trade is free.
Analysts rate BETA BIONICS INC Buy (bullish), based on 11 analysts. Average price target: US$20.31.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
BETA BIONICS INC is a company focused on developing medical devices for diabetes management. It aims to leverage technological innovation to enhance the quality of life for patients.